Related Experiment Videos
Therapy for childhood acute lymphoblastic leukemia
W F Cassano1, A E Eskenazi, C N Frantz
1University of Maryland School of Medicine, Baltimore.
Current Opinion in Oncology
|January 1, 1993
Summary
Advances in childhood acute lymphoblastic leukemia (ALL) therapy stem from laboratory studies of lymphoblasts. These studies improve risk stratification and minimal residual disease detection, though novel, less toxic treatments are still needed.
Area of Science:
- Pediatric Oncology
- Hematology
- Molecular Biology
Background:
- Childhood acute lymphoblastic leukemia (ALL) therapy has advanced through laboratory research on patient lymphoblasts.
- Understanding molecular defects in leukemogenesis aids in developing sensitive tests for minimal residual disease.
Purpose of the Study:
- To review recent advances in childhood ALL therapy.
- To discuss the role of laboratory studies in improving treatment outcomes and identifying new therapeutic strategies.
Main Methods:
- DNA-ploidy determination.
- Analysis of chromosomal translocations.
- In vitro chemosensitivity studies.
- Minimal residual disease detection methods.
Main Results:
- Laboratory findings facilitate risk stratification and outcome prediction in childhood ALL.
- Improved understanding of molecular defects aids in minimal residual disease detection.
- Conventional chemotherapy can have adverse effects, and relapsed ALL treatment remains challenging.
Conclusions:
- Laboratory studies are crucial for advancing childhood ALL therapy.
- Bone marrow transplantation offers improved outcomes for some patients.
- Development of novel, less toxic therapeutic agents is essential for future treatment of ALL.